<DOC>
	<DOCNO>NCT00396487</DOCNO>
	<brief_summary>To compare response rate single agent chemotherapy advance colorectal cancer give standard treatment versus tailor treatment randomised phase III trial .</brief_summary>
	<brief_title>Tailored Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The TS MTHFR polymorphism investigate new study base analysis normal tissue . The result indicate protein 3/3 TS polymorphism MTHFR T polymorphism significantly high response rate long time progression group treat bolus 5-FU . Capecitabine metabolise 5-FU number enzymatic step . It first rationally design drug base upon high concentration thymidine phosphorylase ( TP ) many human tumor compare normal tissue . TP last step conversion capecitabine 5-FU seem limit factor activation . Capecitabine may extent mimic continue 5-FU infusion oppose bolus 5-FU . A number small investigation indicate patient 2R/2R TS polymorphism high response rate heterozygous patient . The TS MTHFR polymorphism analysis easily perform sputum , mean easy collection send sample . At present single agent chemotherapy base three drug ( 5-FU , capecitabine , Irinotecan ) almost overall activity . It seem rational investigate improvement obtain tailor treatment accord gene polymorphism .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Metastatic colorectal cancer Histopathological verification primary tumor Measurable disease accord RESIST criterion Single agent chemotherapy indicate Performance status &gt; =2 Age &gt; = 60 year Life expectancy &gt; 3 month Adequate liver kidney function evaluate bilirubin &lt; = 3 time normal upper limit , ALAT &lt; = 3 time upper normal limit ( &lt; = 5 time upper normal limit case liver metastasis ) , serum creatinine &lt; = 1.5 time normal upper limit . ANC &gt; =1.5 x 109/l platelet &gt; = 100 x 109/l Informed consent Patients CNS metastases Other malignant disease within last 5 year except nonmelanoma skin cancer carcinoma situ cervix uteri Previous chemotherapy metastatic disease Adjuvant chemotherapy &lt; 6 month inclusion Patients previous major toxic allergic reaction protocol drug</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>tailor treatment</keyword>
	<keyword>genetic marker</keyword>
	<keyword>gene polymorphism</keyword>
	<keyword>chemotherapy</keyword>
</DOC>